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Introduction. Cerebral venous sinus thrombosis (CVST) is a rare form of cerebrovascular disease, which may manifest clinically
by a wide variety of signs and symptoms. It has been associated with multiple risk factors including genetic or acquired blood
disorders, infections, and trauma. Case Report. Man of 17 years who presented with 10 days of intense global headache with nausea
and vomiting and subsequent onset of mild hemiparesis and hypoesthesia in right hemibody. Studies show venous thrombosis of
the superior longitudinal sinus. It was identiﬁed a gene mutation in prothrombin G20210A as a probable cause of the thrombosis.
Conclusions. Substitution of guanine for adenine at nucleotide 20210 in the coding region of the prothrombin gene is the second
most common primary thrombophilia. Multiple cases of CVST have been associated with this mutation. In the presence of CVST
must be considered the primary studies for thrombophilia gene mutations, including prothrombin G20210A.
1.Introduction
T h ec e r e b r a lv e n o u ss i n u st h r o m b o s i s( C V S T )i sar a r ef o r m
of stroke corresponding to about 0.5% to 1% of all cases
presentingwiththiscondition.Annualincidenceisestimated
at about 3 to 4 cases per 1 million people, being more
common in women, particularly between the ages of 25 and
35 [1–4].
In the last decades has been increased the number of
diagnosesofthisconditionprobablyduetotheimprovement
in neuroimaging studies, allowing an appropriate treatment
with good outcomes in more than 80% of patients [3].
CVSTcanclinicallymanifestwithawidevarietyofsymp-
toms ranging from mild headache to severe neurological
alterations. Two main mechanisms that explain the signs
andsymptomsincludecerebralvenousthrombosiswithlocal
eﬀectsofobstructionandvenoussinusthrombosisleadingto
intracranial hypertension [3].
The diagnosis should be suspected in young patients
with recent headache or unusual symptoms similar to
those of cerebrovascular disease by arterial thrombosis. In
general, the average time to reach this diagnosis is 7 days
according to published reports [5]. The most sensitive test
for the diagnosis is the cerebral magnetic resonance with
venography [2].
Multiple risk factors have been associated with CVST but
few are reversible. In 85% of cases can be identiﬁed a risk
factor or a direct cause of thrombosis as genetic or acquired
prothrombotic alterations, infectious diseases, inﬂammatory
diseases, hematological conditions, medications, and trauma
[2, 3].
Important genetic prothrombotic conditions include
deﬁciency of antithrombin, protein C or S; factor V Lei-
den, prothrombin G20210A mutation, and hyperhomocys-
teinemia. The prothrombin G20210A mutation has been
associated with venous thrombotic events in unusual places
including cerebral venous sinus. This occurs mainly in
women using oral contraceptives or in physiological states
like pregnancy. We describe an unusual case of CVST in a
young man who has the prothrombin G20210A mutation.
2.CaseReport
A 17-year-old man, high school student, with no relevant
medical history was admitted for 10 days of intense global2 Case Reports in Medicine
Figure 1: Magnetic resonance venography of the brain with supe-
rior longitudinal sinus thrombosis.
headacheaccompaniedbynauseaandvomiting. Hewashos-
pitalized for 4 days before admission at another institution,
where imaging studies were performed with simple brain
scan reported as normal and then discarded central nervous
system infection. The patient was managed with analgesics
and was discharged. For persistence of the headache and
sensorysymptomsincludinghypoesthesiainrighthemibody
withslightlossofmusclestrength,hewasadmittedagain.He
was evaluated by the Neurology Department with a physical
examination which showed a blood pressure of 138/76, heart
rate of 88 beats per minute, and respiratory rate of 17 per
minute, temperature of 37 degrees, neurological exam with
ﬂuent speech, cranial nerves normal, fundus with absence
of venous pulses bilaterally, muscle strength of 3 of 5 in
right hemibody, tendon reﬂexes of +++ numbness in right
hemibody. No nuchal rigidity or other signs of meningitis
were identiﬁed. A new magnetic resonance imaging study
with gadolinium and venography reported cerebral sinus
thrombosis of the superior longitudinal sinus with venous
infarction in subacute phase (Figures 1 and 2). Given the
ﬁndings, it was decided to initiate anticoagulation with
unfractionated heparin and warfarin. Further investigations
ruled out infectious etiology. He was studied for primary
thrombophilia identifying a mutation in the prothrombin
gene with the following test: “Gen F2 was analyzed using
quantitative chain reaction (qPCR) with amplimers and sub-
sequent extension of thermal dissociation curve. Platform
Roche Light Cycler. It conﬁrms the presence of G20210A
mutation in the prothrombin gene. The mutation was found
in heterozygous state, means that the patient has copy of the
mutated gene.”
Figure 2: Sagittal T1 with superior longitudinal sinus thrombosis.
The patient has a total resolution of symptoms and con-
tinues with oral anticoagulation with warfarin.
3. Discussion
The prothrombin gene is located on chromosome 11p.
Substitution of guanine for adenine at nucleotide 20210 in
the coding region of this gene generates increased levels of
prothrombin, the precursor of thrombin, which is essential
component of homeostasis. It is suggested that the increase
in prothrombin levels is the cause of the hypercoagulable
state, generating increased risk of venous thrombotic events
[6]. The prevalence of the mutation is between 0.5% and
4%, mainly present in heterozygous state. Homozygous
presentation is very rare, occurring in 1 in 4000 Caucasian
individuals.
In 1996, Poort et al. described for the ﬁrst time the as-
sociation of the mutation in the prothrombin gene with
increased plasma levels of this, with the resulting increase
in venous thrombosis [7]. In 1998, it was reported the ﬁrst
case of CVST associated with the prothrombin G20210A
mutation by Bloem et al. [8]. From this date, there have been
multiple reports in patients with diﬀerent clinical features,
usually with additional triggers such as pregnancy, oral
contraceptives, among others. In 2006, it was performed a
meta-analysis that included 360 patients with CVST, ﬁnding
that the OR for this mutation reached 9.27 (95% CI 5.85
to 14.67), which is an important association with venous
thromboembolism in general [9].
This paper highlights the case of a young patient with
an intense global headache, in which at 10 days after onset,
CVSTwasdemonstrated.Thetimetothediagnosis,although
prolonged, is in the average range as published in the lit-
erature. This case has unusual aspects, mainly because of
being male patient without precipitating factors in whom
evidenced as the only possible etiology of thrombosis the
presence of the mutation in the gene prothrombin G20210A.Case Reports in Medicine 3
The patient responded appropriately to anticoagulant ther-
apy with complete resolution of symptoms.
4. Conclusions
It is important to consider the diagnosis of CVST in young
patients with recent onset of severe headache and make ap-
propriate studies in search of their cause including primary
thrombophilia testing. The mutation of prothrombin gene
appears as a factor that should always be considered for
proper diagnosis and treatment.
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